Rotavirus

Vaccine candidate shown effective against rotavirus disease in infants

Published in Drug Week, January 27th, 2006

Data from one of the largest infant vaccine trials ever conducted, published in the New England Journal of Medicine, showed GlaxoSmithKline's (GSK) rotavirus vaccine candidate as effective against rotavirus disease (rotavirus gastroenteritis) in the first year of life.

Rotavirus is the leading recognized cause of diarrhea-related illness and death among infants and young children. Every year, rotavirus is associated with an estimated 25 million clinic visits, 2 million hospitalizations, and more than 600,000 deaths worldwide among children younger than 5 years of age.

Results from a double-blind, placebo-controlled trial demonstrated 2 doses...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-01-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry